DBV reports Q3 net loss, $149M cash; FDA clarifies COMFORT studies; terminates Nestlé deal

DBV Technologies S.A.

2023-Q3 EPS reported -$0.65 revenue$6,853,000

FDA provided written feedback harmonizing COMFORT Toddlers/Children protocol design; COMFORT Toddlers uses same eligibility as EPITOPE (DBPCFC required).
Cash $149.1M (Dec 31 2022: $209.2M); 9M 2023 net loss $61.5M ($0.65/share) vs $57.0M loss in 9M 2022.
Terminated Nestlé collaboration (MAG1C atopy patch test) effective Oct 30, 2023; APTITUDE study ended; no further milestones.
First COMFORT Toddlers subject enrollment expected Q1 2024; COMFORT Children start after VITESSE recruitment.

item 1.02 item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

DBV Technologies S.A. reported financial results for third quarter of 2023.

Period: third quarter of 2023
Result: reported results

Exact text from the filing

On October 31, 2023, the Company issued a press release announcing financial results and business highlights for the fiscal quarter ended September 30, 2023.

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

DBV Technologies S.A. terminated Collaboration Agreement with Société des Produits Nestlé S.A. (formerly NESTEC S.A.) (effective 2023-10-30).

Action: termination
Agreement: collaboration
Counterparty: Société des Produits Nestlé S.A. (formerly NESTEC S.A.)
Effective: 2023-10-30

Exact text from the filing

On October 30, 2023, the Company and NESTEC entered into a Mutual Termination Letter Agreement terminating the Collaboration Agreement.

View on SEC.gov

Browse all earnings releases →

DBV Technologies S.A. filing history →

Source: SEC EDGAR

accession 0001193125-23-267275

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.